THIOPHENDERIVATE

European patent · EP3793989 · In force

Register entry

Publication number
EP3793989
Application number
EP19723796
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
May 15, 2019
Published
Mar 24, 2021
Granted
Aug 21, 2024
Protection ends at the latest
May 14, 2039
Next annual fee due
May 31, 2027
IPC classes
C07D 333/72 (2006.01)
C07D 333/78 (2006.01)
C07D 409/04 (2006.01)
A61P 35/00 (2006.01)
A61K 31/381 (2006.01)
Priority
EP 18173069 18.05.2018
PCT application
PCT/EP2019/062438 15.05.2019
PCT publication
WO2019/219731 21.11.2019
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jun 1, 2026

    Change

    Published in Swissreg on 01.06.2026

  2. Jul 2, 2025

    Change

    Published in Swissreg on 02.07.2025

  3. Jun 1, 2025

    Change

    Published in Swissreg on 01.06.2025

  4. Aug 21, 2024

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 21.08.2024

Parties

Holder

Merck Patent GmbH

Frankfurter Strasse 250, 64293 Darmstadt, DE

Ryvu Therapeutics S.A.

ul. Bobrzynskiego 14, 30-348 Krakow, PL

Inventor

BUCHSTALLER, Hans-Peter

64347 GRIESHEIM, DE

MATTHIAS, Leiendecker

64293 Darmstadt, DE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.